Allergen immunotheraphy - A position paper of the German society for allergology and clinical immunology;Die spezifische immuntherapie (hyposensibilisierung) mit allergenen: Positionspapier der deutschen gesellschaft für allergologie und klinische immunologie inhaltlich abgestimmt mit dem ärzteverband deutscher allergologen

Pneumologie

Volumn 55, Issue 9, 2001, Pages 438-444

  Kleine Tebbe, J ^a   Fuchs, T ^a   Klimek, L ^a   Kuhr J ^a   Lepp, U ^a   Niggemann, B ^a   Rakoski, J ^a   Renz, H ^a   Saloga, J ^a   Simon, J ^a  

^a DGAI ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; BEE VENOM; IMMUNOGLOBULIN E; IMMUNOLOGICAL ADJUVANT; RECOMBINANT PROTEIN; WASP VENOM;

ADULT; ALLERGIC ASTHMA; CHILD; CONFERENCE PAPER; DRUG EFFICACY; GERMANY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOTHERAPY; INFLAMMATION; MEDICAL SOCIETY; PRIORITY JOURNAL; RHINOCONJUNCTIVITIS; RISK FACTOR; SENSITIZATION; T LYMPHOCYTE;

ALLERGENS; DESENSITIZATION, IMMUNOLOGIC; GERMANY; HUMANS; RESPIRATORY HYPERSENSITIVITY; TREATMENT OUTCOME;

EID: 0034807814     PISSN: 09348387     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-16954     Document Type: Conference Paper

References (37)

1. The use of standardized allergen extracts. Position statement
2. Immunotherapy in asthma: An updated systematic review
3. Is allergen immunotherapy effective in asthma? A metaanalysis of randomized controlled trials
4. Mechanisms of allergen-specific immunotherapy
5. Hyposensitization with a tyrosine adsorbed extract of Dermatophagoides pteronyssinus in adults with perennial rhinitis
6. Differences in clinical and immunologic reactivity of patients allergic to grass pollens and to multiple-pollen species. II. Efficacy of a double-blind, placebo-controlled, specific immunotherapy with standardized extracts
7. Allergen immunotherapy: Therapeutic vaccines for allergic diseases. WHO position paper
8. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. III. Efficacy and safety of unfractionated and high-molecular-weight preparations in rhinoconjunctivitis and asthma
9. Immunotherapy with Hymenoptera venoms. Position paper of the Working Group on Immunotherapy of the European Academy of Allergy and Clinical Immunology
10. Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: A double-blind, placebo-controlled study
11. Immunotherapy with dog and cat allergen preparations in dog-sensitive and cat-sensitive asthmatics
12. Immunotherapy with Alpare® in patients with respiratory allergy to Parietaria pollen: A two year double-blind placebo-controlled study
13. A double-blind, placebo-controlled study of immunotherapy with grass-pollen extract Alutard SQ during a 3-year period with initial rush immunotherapy
14. Allergen standardization and skin tests. EAACI position paper
15. Dose dependence of Hymenoptera venom immunotherapy
16. The safety and activity of polymerized ragweed: A double-blind, placebo-controlled trial in 81 patients with ragweed rhinitis
17. Risk of systemic reactions in patients taking beta-blocker drugs receiving allergen immunotherapy injections
18. Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite extract (D.pt.) in children
19. Double-blind, placebo-controlled rush immunotherapy with a standardized Alternaria extract
20. Immunotherapy with partially purified and standardized tree pollen extracts. IV. Results from long-term 6-year follow-up
21. Double-blind placebo-controlled evaluation of sunlingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis
22. Immunotherapy. Position Paper of the European Academy of Allergology and Clinical Immunology (EAACI)
23. Clustered immunotherapy with yellow jacket venom. Evaluation of the influence of time interval on in vivo and in vitro parameters
24. Immunotherapy with yellow jacket venom. A comparative study including three different extracts, one adsorbed to aluminium hydroxide and two unmodified
25. Honeybee venom allergy: Results of a sting challenge 1 year after stopping successful venom immunotherapy in 86 patients
26. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety
27. Immunotherapy with Hymenoptera venoms. Position paper
28. A double-blind randomized study investigating the efficacy and specificity of immunotherapy with Artemisia vulgaris or Phleum pratense/Betula verrucosa
29. Clinical and immunological effects of immunotherapy with alum-absorbed grass allergoid in grass-pollen-induced hay fever
30. Specific immunotherapy with Dermatophagoides pteronyssinus and D. farinae results in decreased bronchial hyperreactivity
31. Sublingual-swallow immunotherapy (SLIT) with a standardized five-grass-pollen extract (drops and sublingual tablets) versus placebo in seasonal rhinitis
32. Diagnose und therapie der bienen- und wespengiftallergie - Positionspapier der Deutschen Gesellschaft für Allergologie und klinische Immunologie (DGAI)
33. Empfehlungen zur hyposensibilisierung mit allergenextrakten
34. Immunotherapy with an alum-adsorbed Parietaria-pollen allergoid: A 2-year, double-blind, placebo-controlled study
35. Akuttherapie anaphylaktoider reaktionen
36. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs
37. Rush venom immunotherapy program for honeybee sting sensitivity